Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Paolo Caimi, MD
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07225439CT.gov Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | — | Not Yet Recruiting | — | — | — |
NCT07024147CT.gov JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT05077527CT.gov Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT07168486CT.gov CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | — | Enrolling By Invitation | — | — | — |
NCT06486051CT.gov A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT06093841CT.gov Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL | — | Active Not Recruiting | — | — | — |
NCT06026319CT.gov CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT05633615CT.gov Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT05665062CT.gov Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | — | Active Not Recruiting | — | — | — |
NCT05605899CT.gov Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
Show 25 more trialsShow fewer
NCT05694364CT.gov Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | — | Completed | — | — | — |
NCT05653271CT.gov ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | — | Active Not Recruiting | — | — | — |
NCT05359211CT.gov NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05108805CT.gov Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting | — | Completed | — | — | — |
NCT04855253CT.gov Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL | — | Suspended | — | — | — |
NCT04735471CT.gov A Phase 1 Study of ADI-001 in B Cell Malignancies | — | Terminated | — | — | — |
NCT04836507CT.gov Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients | — | Recruiting | — | — | — |
NCT04767308CT.gov Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | — | Unknown | — | — | — |
NCT04195633CT.gov Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | — | Recruiting | — | — | — |
NCT04545762CT.gov Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT04432506CT.gov Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma | — | Completed | — | — | — |
NCT04323657CT.gov TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT04205838CT.gov Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | — | Terminated | — | — | — |
NCT04088890CT.gov Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | — | Completed | — | — | — |
NCT03676504CT.gov Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | — | Recruiting | — | — | — |
NCT03044743CT.gov PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | — | Unknown | — | — | — |
NCT03049449CT.gov T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | — | Completed | — | — | — |
NCT01962636CT.gov Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | — | Terminated | — | — | — |
NCT02706405CT.gov JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT02431988CT.gov Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation | — | Completed | — | — | — |
NCT02685670CT.gov Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma | — | Unknown | — | — | — |
NCT01163201CT.gov T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | — | Withdrawn | — | — | — |
NCT01181271CT.gov Tandem Auto-Allo Transplant for Lymphoma | — | Completed | — | — | — |
NCT01144403CT.gov A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. | — | Terminated | — | — | — |
NCT00924326CT.gov CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | Paolo Caimi, MD | Approved | BB · 65 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | A |
| Melphalan | Ruijin Hospital | P4 | BBB |
| Axicabtagene Ciloleucel | Ruijin Hospital | P4 | BBB |
| Adriamycin | Beth Israel Deaconess Medical Center | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Nivestim | Ruijin Hospital | P3 | BBB |
| Rituximab | Beth Israel Deaconess Medical Center | P4 | BBB |
+42 more in the Diffuse Large B-Cell Lymphoma cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fludarabine in Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-diffuse-large-b-cell-lymphoma-3330
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →